Tadalafil Market Report 2026

Tadalafil Market Overview

• Tadalafil market size has reached to $5.53 billion in 2025 • Expected to grow to $9.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.1% • Growth Driver: Increasing Prevalence Of Erectile Dysfunction Driving Growth In The Market • Market Trend: Improving Market Share Through Novel Combination Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tadalafil Market?

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor used primarily to treat erectile dysfunction and pulmonary arterial hypertension. It works by relaxing blood vessels, improving blood flow to specific areas, and helping to manage these conditions effectively. The main product types of tadalafil are tablets and oral suspensions. Tadalafil tablets are solid, oral medications that provide precise dosing, are convenient for patient use, and are widely prescribed for conditions like erectile dysfunction due to their effectiveness and ease of administration. The various distributed channels include hospital pharmacies, retail pharmacies, and online pharmacies. It is used for different applications like erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.

What Is The Tadalafil Market Growth Forecast?

The tadalafil market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing aging male population, rising acceptance of online prescription platforms, growing focus on chronic disease management, expansion of combination therapy research, increasing access to affordable generic medications. Major trends in the forecast period include increasing adoption of generic tadalafil formulations, rising demand for long-acting pde5 inhibitors, expansion of online pharmacy distribution, growing focus on patient-centric dosing options, improved manufacturing efficiency for oral solid dosage.

Global Tadalafil Market Segmentation

1) By Product Type: Tablets, Oral Suspensions 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Application: Erectile Dysfunction, Pulmonary Arterial Hypertension, Benign Prostatic Hyperplasia Subsegments: 1) By Tablets: 2.5 mg Tablets, 5 mg Tablets, 10 mg Tablets, 20 mg Tablets 2) By Oral Suspensions: 2.5 mg/5 mL Oral Suspension, 10 mg Oral Suspension, Custom Dosing Oral Suspensions

What Is The Driver Of The Tadalafil Market?

The increase in the prevalence of erectile dysfunction is expected to propel the growth of the tadalafil market going forward. Erectile dysfunction (ED) is a medical condition characterized by the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. The increase in the prevalence of erectile dysfunction (ED) is largely due to factors such as an aging population, chronic health conditions, poor lifestyle choices, psychological stress, and the side effects of certain medications. Tadalafil helps erectile dysfunction by relaxing the smooth muscles in the blood vessels of the penis, enhancing blood flow, and enabling the ability to achieve and sustain an erection during sexual stimulation. For instance, in February 2024, according to a report published by the National Library of Medicine, a US-based National Institutes of Health (NIH), the prevalence of erectile dysfunction (ED), measured using IIEF-5 scores, is 24.2% across the general population. The incidence significantly rises with age, affecting 52.2% of individuals aged 75 and older and 48.0% of those in the 65-74 age group. Therefore, the increase in the prevalence of erectile dysfunction is driving the growth of the tadalafil industry.

Key Players In The Global Tadalafil Market

Major companies operating in the tadalafil market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Jubilant Pharma Limited, Jiangsu Lianhuan Pharmaceutical Co. Ltd., Alembic Pharmaceuticals Limited, Polpharma SA, SMS Pharmaceuticals Limited, Camber Pharmaceuticals Inc., Century Pharmaceuticals Limited, Rakshit Drugs Private Limited, Ami Lifesciences Private Limited, Hangzhou Longshine Bio-Tech Co. Ltd., Dolphin Pharmaceuticals

Global Tadalafil Market Trends and Insights

Major companies operating in the tadalafil market are focusing on innovative formulations, such as combination therapy, to enhance treatment efficacy, improve patient compliance, and expand their market share in the management of erectile dysfunction and pulmonary arterial hypertension. Combination therapy is the use of two or more medications or treatments simultaneously to enhance therapeutic outcomes, improve efficacy, and address multiple aspects of a disease or condition. For instance, in March 2024, Johnson & Johnson, a US-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) has granted approval for OPSYNVI, a single-tablet therapy combining macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. This innovative treatment is indicated for the chronic management of pulmonary arterial hypertension (PAH) (WHO Group I) in adult patients classified under WHO functional class II-III. OPSYNVI is suitable for treatment-naïve patients as well as those currently on ERA, PDE5 inhibitors, or both therapies. Additionally, it offers a streamlined option for patients stabilized on macitentan 10 mg and tadalafil 40 mg (20 mg x 2) administered separately.

What Are Latest Mergers And Acquisitions In The Tadalafil Market?

In February 2024, Zuellig Pharma Holdings Ltd., a Singapore-based company provides healthcare solutions, acquired Cialis (Tadalafil) and Alimta (Pemetrexed) from Eli Lilly and Company for an undisclosed amount. With this acquisition, Zuellig Pharma aims to expand its portfolio of pharmaceutical products, strengthen its market presence, and enhance its ability to meet the growing demand for treatments addressing erectile dysfunction (Cialis) and cancer (Alimta) across its operational regions. Eli Lilly and Company is a US-based company that produces tadalafil-based treatments for erectile dysfunction and pulmonary arterial hypertension.

Regional Outlook

North America was the largest region in the tadalafil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tadalafil Market?

The tadalafil market consists of sales of injectable formulations, extended-release formulations, and topical formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tadalafil Market Report 2026?

The tadalafil market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tadalafil industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.